Legend Biotech & Janssen Ink Supply Deal
Ticker: LEGN · Form: 6-K · Filed: Oct 7, 2025 · CIK: 1801198
| Field | Detail |
|---|---|
| Company | Legend Biotech Corp (LEGN) |
| Form Type | 6-K |
| Filed Date | Oct 7, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: supply-agreement, pharmaceuticals, car-t
Related Tickers: LBTH
TL;DR
Legend Biotech inks supply deal with Janssen for CAR-T therapy components.
AI Summary
On October 6, 2025, Legend Biotech USA Inc., a subsidiary of Legend Biotech Corporation, entered into a Component and Product Supply Agreement with Janssen Pharmaceuticals, Inc. This agreement outlines the terms for the supply of components and finished products related to Legend Biotech's CAR-T therapy.
Why It Matters
This agreement solidifies the supply chain for Legend Biotech's CAR-T therapy, crucial for its commercialization and ongoing development.
Risk Assessment
Risk Level: low — The filing is a routine update on a supply agreement, not indicating new financial distress or significant operational changes.
Key Players & Entities
- Legend Biotech USA Inc. (company) — Subsidiary entering agreement
- Legend Biotech Corporation (company) — Parent company
- Janssen Pharmaceuticals, Inc. (company) — Party to the supply agreement
- October 6, 2025 (date) — Execution date of the agreement
FAQ
What is the nature of the agreement between Legend Biotech USA Inc. and Janssen Pharmaceuticals, Inc.?
The agreement is a Component and Product Supply Agreement, detailing the terms for supplying components and finished products for Legend Biotech's CAR-T therapy.
When was the agreement executed?
The agreement was executed on October 6, 2025.
What is the relationship between Legend Biotech USA Inc. and Legend Biotech Corporation?
Legend Biotech USA Inc. is a wholly-owned subsidiary of Legend Biotech Corporation.
What specific product is the supply agreement related to?
The agreement is related to Legend Biotech's CAR-T therapy.
What is the filing type and date?
This is a Form 6-K filed on October 7, 2025.
Filing Stats: 643 words · 3 min read · ~2 pages · Grade level 16.9 · Accepted 2025-10-07 16:01:48
Filing Documents
- f6k_100725.htm (6-K) — 13KB
- 0001171843-25-006329.txt ( ) — 14KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LEGEND BIOTECH CORPORATION Date: October 7, 2025 By: /s/ Ying Huang Name: Ying Huang, Ph.D. Title: Chief Executive Officer